• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's Pre-Market Session

    3/25/24 9:05:53 AM ET
    $AKAN
    $CYTO
    $ESPR
    $LABP
    Medicinal Chemicals and Botanical Products
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AKAN alert in real time by email

    Gainers

    • Landos Biopharma (NASDAQ:LABP) shares moved upwards by 181.6% to $22.05 during Monday's pre-market session. The market value of their outstanding shares is at $68.7 million. As per the press release, Q4 earnings came out 2 days ago.
    • Altamira Therapeutics (NASDAQ:CYTO) shares rose 49.71% to $2.59. The market value of their outstanding shares is at $4.7 million.
    • Esperion Therapeutics (NASDAQ:ESPR) stock increased by 21.83% to $2.79. The company's market cap stands at $516.2 million.
    • Salarius Pharmaceuticals (NASDAQ:SLRX) shares moved upwards by 21.66% to $0.75. The company's market cap stands at $2.9 million. As per the news, the Q4 earnings report came out yesterday.
    • Neuronetics (NASDAQ:STIM) stock increased by 18.19% to $5.0. The market value of their outstanding shares is at $148.7 million.
    • Nkarta (NASDAQ:NKTX) stock rose 17.93% to $10.52. The market value of their outstanding shares is at $516.2 million. As per the news, the Q4 earnings report came out 2 days ago.

    Losers

    • SINTX Techs (NASDAQ:SINT) stock declined by 46.5% to $0.05 during Monday's pre-market session.
    • Akanda (NASDAQ:AKAN) stock declined by 32.2% to $0.17. The market value of their outstanding shares is at $1.4 million.
    • Trxade Health (NASDAQ:MEDS) stock declined by 30.42% to $16.75. The market value of their outstanding shares is at $20.1 million.
    • Nuvation Bio (NYSE:NUVB) shares declined by 18.62% to $1.88. The company's market cap stands at $411.8 million.
    • Yield10 Bioscience (NASDAQ:YTEN) stock fell 11.82% to $0.33. The market value of their outstanding shares is at $3.9 million.
    • Virios Therapeutics (NASDAQ:VIRI) stock declined by 9.27% to $0.41. The market value of their outstanding shares is at $7.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AKAN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AKAN
    $CYTO
    $ESPR
    $LABP

    CompanyDatePrice TargetRatingAnalyst
    Esperion Therapeutics Inc.
    $ESPR
    11/25/2025$9.00Overweight
    Piper Sandler
    Nuvation Bio Inc.
    $NUVB
    11/24/2025Buy
    Truist
    Nuvation Bio Inc.
    $NUVB
    11/19/2025$12.00Buy
    B. Riley Securities
    Nuvation Bio Inc.
    $NUVB
    9/30/2025$10.00Buy
    Jefferies
    Nkarta Inc.
    $NKTX
    5/15/2025Outperform → Mkt Perform
    William Blair
    Nuvation Bio Inc.
    $NUVB
    4/23/2025$6.00Mkt Outperform
    Citizens JMP
    Esperion Therapeutics Inc.
    $ESPR
    12/18/2024$4.00Neutral
    Goldman
    Esperion Therapeutics Inc.
    $ESPR
    12/17/2024$8.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $AKAN
    $CYTO
    $ESPR
    $LABP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Moyes Jay M bought $2,910 worth of shares (1,000 units at $2.91), increasing direct ownership by 33% to 4,000 units (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    2/25/26 9:00:02 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Director Anderson Mark Lewis bought $9,060 worth of shares (3,000 units at $3.02), increasing direct ownership by 20% to 18,000 units (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    2/19/26 9:00:04 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Large owner Hrt Financial Lp bought $40,650 worth of Class A Shares (29,036 units at $1.40) and sold $10,150 worth of Class A Shares (7,868 units at $1.29) (SEC Form 4)

    4 - AKANDA CORP. (0001888014) (Issuer)

    1/20/26 2:07:19 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    $AKAN
    $CYTO
    $ESPR
    $LABP
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for NEXLIZET issued to ESPERION THERAPS INC

    Submission status for ESPERION THERAPS INC's drug NEXLIZET (SUPPL-16) with active ingredient BEMPEDOIC ACID; EZETIMIBE has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211617, Application Classification: Efficacy

    3/25/24 4:41:30 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for NEXLIZET issued to ESPERION THERAPS INC

    Submission status for ESPERION THERAPS INC's drug NEXLIZET (SUPPL-17) with active ingredient BEMPEDOIC ACID; EZETIMIBE has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211617, Application Classification: Efficacy

    3/25/24 4:41:37 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for NEXLETOL issued to ESPERION THERAPS INC

    Submission status for ESPERION THERAPS INC's drug NEXLETOL (SUPPL-13) with active ingredient BEMPEDOIC ACID has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211616, Application Classification: Efficacy

    3/25/24 4:41:29 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKAN
    $CYTO
    $ESPR
    $LABP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, CLO and CS Macan William Andrew sold $816 worth of shares (609 units at $1.34), decreasing direct ownership by 0.07% to 879,525 units (SEC Form 4)

    4 - Neuronetics, Inc. (0001227636) (Issuer)

    3/6/26 4:29:47 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by CHIEF MEDICAL OFFICER Liu Dongfang

    4 - Nuvation Bio Inc. (0001811063) (Issuer)

    3/3/26 8:04:44 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Makunje Moses was granted 50,761 shares, increasing direct ownership by 292% to 68,137 units (SEC Form 4)

    4 - Nuvation Bio Inc. (0001811063) (Issuer)

    3/3/26 8:03:31 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKAN
    $CYTO
    $ESPR
    $LABP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Piper Sandler initiated coverage on Esperion Therapeutics with a new price target

    Piper Sandler initiated coverage of Esperion Therapeutics with a rating of Overweight and set a new price target of $9.00

    11/25/25 8:41:48 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Truist initiated coverage on Nuvation Bio

    Truist initiated coverage of Nuvation Bio with a rating of Buy

    11/24/25 8:30:57 AM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    B. Riley Securities initiated coverage on Nuvation Bio with a new price target

    B. Riley Securities initiated coverage of Nuvation Bio with a rating of Buy and set a new price target of $12.00

    11/19/25 8:57:29 AM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKAN
    $CYTO
    $ESPR
    $LABP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    HLS Therapeutics Announces NILEMDOTM (bempedoic acid) is now available in Canada for the Reduction of LDL-Cholesterol in Patients at Risk of Cardiovascular Disease

    First-in-class, once-daily oral non-statin therapy now available by prescription across CanadaAddresses a significant unmet need for over half a million Canadians who can not get to their LDL-C goal on statin-based therapy or who are statin intolerantSupported by the landmark CLEAR Outcomes trial demonstrating reduction in major adverse cardiovascular events in nearly 14,000 patientsTORONTO, March 5, 2026 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, today announced the commercial launch of NILEMDO™ (bempedoic acid) in Canada. NILEMDO is now ava

    3/5/26 7:00:00 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Neuronetics to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call

    MALVERN, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc., (NASDAQ:STIM) (the "Company" or "Neuronetics"), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced that it plans to release fourth quarter 2025 financial and operating results prior to market open on Tuesday, March 17, 2026. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-serv

    3/3/26 8:30:00 AM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Esperion Therapeutics and Corstasis Therapeutics Announce Esperion's Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

    – Enbumyst™ Is the First and Only FDA-Approved Nasal Spray Loop Diuretic for Edema Associated with Congestive Heart Failure, Expected to Leverage Esperion's Established Cardiovascular Commercial Infrastructure, Synergistically Expand Product Portfolio and Accelerate Double-Digit Revenue Growth – – Upfront Cash Payment of $75 Million, Royalties on Worldwide Enbumyst Sales and Up to $180 Million in Potential Milestone Payments Tied to Certain Commercial and Regulatory Achievements – – Esperion to Host Conference Call on Tuesday, March 3, 2026 at 8:00 am ET – ANN ARBOR, Mich. and HENDERSON, Nev., March 03, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) and Corstasis Therapeutics Inc., a p

    3/3/26 6:00:00 AM ET
    $ESPR
    $KKR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Investment Managers
    Finance

    $AKAN
    $CYTO
    $ESPR
    $LABP
    SEC Filings

    View All

    SEC Form S-8 filed by Nuvation Bio Inc.

    S-8 - Nuvation Bio Inc. (0001811063) (Filer)

    3/3/26 4:07:01 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Esperion Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Esperion Therapeutics, Inc. (0001434868) (Filer)

    3/3/26 7:03:05 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Nuvation Bio Inc.

    10-K - Nuvation Bio Inc. (0001811063) (Filer)

    3/2/26 4:49:05 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKAN
    $CYTO
    $ESPR
    $LABP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Neuronetics Inc.

    SC 13D - Neuronetics, Inc. (0001227636) (Subject)

    12/17/24 9:15:11 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Nkarta Inc.

    SC 13G - Nkarta, Inc. (0001787400) (Subject)

    12/13/24 5:02:47 PM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by SiNtx Technologies Inc.

    SC 13G/A - Sintx Technologies, Inc. (0001269026) (Subject)

    11/14/24 7:25:52 PM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    $AKAN
    $CYTO
    $ESPR
    $LABP
    Leadership Updates

    Live Leadership Updates

    View All

    Diality Appoints Peter Donato as Chief Financial Officer

    Life sciences veteran brings private and public sector expertise to company in midst of growth trajectory Diality Inc., a medical device company that has developed the Moda-flx™ Hemodialysis System, today announced it has named Peter Donato as its chief financial officer. Donato joins the company as it continues to enroll patients in the PRESCRIBE Diality Home Hemodialysis Clinical Trial of its Moda-flx Hemodialysis System while preparing for a limited market release in 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224064413/en/Diality CFO Peter Donato. Donato joins Diality with nearly 35 years of financial leadershi

    2/24/26 7:05:00 AM ET
    $MYGN
    $STIM
    $TFX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Medical/Dental Instruments
    Pharmaceuticals and Biotechnology

    SINTX Technologies Appoints Ryan Elmore President to Lead Channel Expansion of Silicon Nitride Biomaterial Platforms

    Appointment supports acceleration of revenue opportunities from SiNERGY™ silicon nitride devices and antipathogenic fibrous material technologies SALT LAKE CITY, Utah, Feb. 18, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics and biomaterials company focused on silicon nitride (SiN) solutions for medical and other high-value applications, today announced the appointment of Ryan Elmore as President of SINTX Technologies, Inc., effective March 16, 2026. Mr. Elmore most recently served as Core Business Director at Invibio, a division of Victrex plc. With more than 15 years of experience in advanced biomaterials and medical dev

    2/18/26 8:30:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Esperion Appoints Industry Veteran John Harlow as Chief Commercial Officer

    – Brings Extensive Executive Leadership Driving Commercial Strategies That Enhance Sales and Marketing Performance – ANN ARBOR, Mich., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced the appointment of John Harlow as the Company's Chief Commercial Officer, effective November 17, 2025. Mr. Harlow will join Esperion's Executive Leadership Team and will report directly to Sheldon Koenig, President and CEO of Esperion.    "We are thrilled to welcome John as our Chief Commercial Officer at such a pivotal time in Esperion's growth, as we continue to expand adoption of our products in the U.S. and increase our global footprint," said Koenig. "John's deep domain expertise

    11/4/25 8:00:00 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKAN
    $CYTO
    $ESPR
    $LABP
    Financials

    Live finance-specific insights

    View All

    Neuronetics to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call

    MALVERN, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc., (NASDAQ:STIM) (the "Company" or "Neuronetics"), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced that it plans to release fourth quarter 2025 financial and operating results prior to market open on Tuesday, March 17, 2026. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-serv

    3/3/26 8:30:00 AM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Esperion Therapeutics and Corstasis Therapeutics Announce Esperion's Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

    – Enbumyst™ Is the First and Only FDA-Approved Nasal Spray Loop Diuretic for Edema Associated with Congestive Heart Failure, Expected to Leverage Esperion's Established Cardiovascular Commercial Infrastructure, Synergistically Expand Product Portfolio and Accelerate Double-Digit Revenue Growth – – Upfront Cash Payment of $75 Million, Royalties on Worldwide Enbumyst Sales and Up to $180 Million in Potential Milestone Payments Tied to Certain Commercial and Regulatory Achievements – – Esperion to Host Conference Call on Tuesday, March 3, 2026 at 8:00 am ET – ANN ARBOR, Mich. and HENDERSON, Nev., March 03, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) and Corstasis Therapeutics Inc., a p

    3/3/26 6:00:00 AM ET
    $ESPR
    $KKR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Investment Managers
    Finance

    Nuvation Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    Successfully started 216 patients on IBTROZI® (taletrectinib) in the fourth quarter of 2025, for a total of 432 new patient starts since launch in the second half of June 2025Entered into exclusive licensing and collaboration agreement with Eisai on January 11, 2026, for taletrectinib in Europe and additional countries outside U.S., China and JapanPublished positive Phase 2 study results for safusidenib demonstrating durable responses for the treatment of grade 2 IDH1-mutant gliomaStrong balance sheet with cash, cash equivalents, and marketable securities of $529.2 million as of December 31, 2025Company to host a conference call today at 4:30 pm ETNEW YORK, March 2, 2026 /PRNewswire/ -- Nuva

    3/2/26 4:05:00 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care